发布于: 雪球转发：0回复：9喜欢：6

$Pandion Therapeutics(PAND)$ 被默克20亿收购。。这公司只有一个IL2靶点的1期资产啊。。就值20亿？？！ 瞬间我感觉手里30多亿的小药企很香了。。。[捂脸]

全部讨论

pktong
2021-02-25 22:43

传奇

重仓时代机会
2021-02-25 22:18

瞬间感觉恒瑞不贵了

JBTFD
2021-02-25 22:15

手里啥小药企啊

握力满满
2021-02-26 01:46

我手里有个10亿美元的销售额1亿美元的小药企呢。日本GNI集团啊。

宅凹克
2021-02-26 00:21

arvn

征途苍穹
2021-02-25 23:37

现在研究创新药，投入产出比感觉很高呀

个人陈述
2021-02-25 23:04

A字头？俺也有

pupppppy
2021-02-25 22:29

The company’s lead candidate, PT101, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases. Earlier this year, Pandion announced that PT101 had completed a Phase 1a clinical trial, which achieved its primary objective of safety and tolerability. The company’s pipeline also includes PD-1 agonists in development for numerous autoimmune diseases.
还有个PD1